The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

OnCusp Therapeutics receives US FDA fast track designation for CUSP06 for treatment of platinum-resistant ovarian cancer: Princeton, New Jersey Saturday, February 15, 2025, 15:00 ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

In this webinar, Daryl Cole will share insights into the high-throughput screening and analysis of antibody binding and functional characterization.

NORTH CHICAGO, IL and WALTHAM, MA, USA I 12, 2025 I AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology ...

"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...